PARP-话题@MedSci

#PARP#

95篇内容 | 2761人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621377, encodeId=583a16213e78d, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=恒瑞医药PARP抑制剂获批上市, objectType=article, longId=204504, objectId=4eb920450478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb920450478, replyNumber=0, likeNumber=97, createdTime=2020-12-16, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb920450478, moduleTitle=恒瑞医药PARP抑制剂获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb920450478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621376, encodeId=09e216213e654, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Eur Urol：ATM缺失的晚期前列腺癌：PARP和ATR抑制剂, objectType=article, longId=204467, objectId=de6a20446ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de6a20446ede, replyNumber=0, likeNumber=91, createdTime=2020-12-15, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de6a20446ede, moduleTitle=Eur Urol：ATM缺失的晚期前列腺癌：PARP和ATR抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de6a20446ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621375, encodeId=6cf616213e56c, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=PARP抑制剂Lynparza在欧洲获得重大成功！同时获批治疗卵巢癌和前列腺癌, objectType=article, longId=203200, objectId=12e720320011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12e720320011, replyNumber=0, likeNumber=89, createdTime=2020-11-11, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12e720320011, moduleTitle=PARP抑制剂Lynparza在欧洲获得重大成功！同时获批治疗卵巢癌和前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12e720320011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621374, encodeId=e11e16213e4fe, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=J Clin Oncol：携带PALB2胚系突变的乳腺癌患者也可从PARPi治疗中获益, objectType=article, longId=202809, objectId=253d202809c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=253d202809c6, replyNumber=0, likeNumber=92, createdTime=2020-11-04, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=253d202809c6, moduleTitle=J Clin Oncol：携带PALB2胚系突变的乳腺癌患者也可从PARPi治疗中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=253d202809c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621373, encodeId=ab9e16213e30e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO, objectType=article, longId=200959, objectId=4aa820095905, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aa820095905, replyNumber=0, likeNumber=94, createdTime=2020-09-21, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aa820095905, moduleTitle=中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aa820095905)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621372, encodeId=9dc016213e274, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代, objectType=article, longId=200929, objectId=978320092943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978320092943, replyNumber=0, likeNumber=158, createdTime=2020-09-21, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978320092943, moduleTitle=Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=978320092943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621371, encodeId=45aa16213e14b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, objectType=article, longId=200007, objectId=6f2b20000e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2b20000e60, replyNumber=0, likeNumber=69, createdTime=2020-08-30, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2b20000e60, moduleTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f2b20000e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621370, encodeId=279f16213e0e8, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=新型PARP抑制剂Stenoparib：在临床前研究中显示出抗新冠病毒活性！, objectType=article, longId=199956, objectId=9299199956cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9299199956cc, replyNumber=0, likeNumber=83, createdTime=2020-08-28, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9299199956cc, moduleTitle=新型PARP抑制剂Stenoparib：在临床前研究中显示出抗新冠病毒活性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9299199956cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621369, encodeId=0cd81621369e9, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查, objectType=article, longId=196133, objectId=03921961335e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03921961335e, replyNumber=0, likeNumber=82, createdTime=2020-06-21, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03921961335e, moduleTitle=姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03921961335e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621368, encodeId=06271621368a4, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗, objectType=article, longId=195327, objectId=2cf719532e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cf719532e2a, replyNumber=0, likeNumber=89, createdTime=2020-06-06, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cf719532e2a, moduleTitle=欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cf719532e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621367, encodeId=da0d162136e62, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌, objectType=article, longId=194609, objectId=150b19460996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=150b19460996, replyNumber=0, likeNumber=70, createdTime=2020-05-24, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=150b19460996, moduleTitle=FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=150b19460996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621366, encodeId=87be162136604, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=尹如铁教授：HRD检测扩大复发性卵巢癌后线治疗获益人群，国内产品首次用于PARPi临床试验入组HRD检测, objectType=article, longId=194408, objectId=c521194408e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c521194408e5, replyNumber=0, likeNumber=97, createdTime=2020-05-21, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c521194408e5, moduleTitle=尹如铁教授：HRD检测扩大复发性卵巢癌后线治疗获益人群，国内产品首次用于PARPi临床试验入组HRD检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c521194408e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621365, encodeId=43cd1621365f1, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Rubraca在美国获批，成为获批治疗前列腺癌的PARP抑制剂, objectType=article, longId=194252, objectId=942519425263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=942519425263, replyNumber=0, likeNumber=69, createdTime=2020-05-18, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=942519425263, moduleTitle=Rubraca在美国获批，成为获批治疗前列腺癌的PARP抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=942519425263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621364, encodeId=f993162136491, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, objectType=article, longId=193374, objectId=b40b1933e4d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40b1933e4d3, replyNumber=0, likeNumber=77, createdTime=2020-05-03, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40b1933e4d3, moduleTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40b1933e4d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621363, encodeId=d15b162136310, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, objectType=article, longId=192958, objectId=e2db19295879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2db19295879, replyNumber=0, likeNumber=58, createdTime=2020-04-27, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2db19295879, moduleTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2db19295879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621362, encodeId=ae1c1621362ca, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, objectType=article, longId=192539, objectId=63c019253993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63c019253993, replyNumber=0, likeNumber=62, createdTime=2020-04-21, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63c019253993, moduleTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63c019253993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621361, encodeId=60f01621361e6, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查, objectType=article, longId=192482, objectId=1c3c1924827f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c3c1924827f, replyNumber=0, likeNumber=111, createdTime=2020-04-20, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c3c1924827f, moduleTitle=再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c3c1924827f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621360, encodeId=0fee162136011, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=70, createdTime=2020-03-16, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621359, encodeId=5a51162135992, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Nat Commun：PARP1通过上调Runx2促进血管钙化, objectType=article, longId=188923, objectId=1f7e188923d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f7e188923d1, replyNumber=0, likeNumber=73, createdTime=2020-02-29, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f7e188923d1, moduleTitle=Nat Commun：PARP1通过上调Runx2促进血管钙化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f7e188923d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621358, encodeId=c84f162135844, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, objectType=article, longId=188795, objectId=27b9188e9585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27b9188e9585, replyNumber=0, likeNumber=68, createdTime=2020-02-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27b9188e9585, moduleTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27b9188e9585)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PARP

2020-05-29

lishiwen (审核中...)

前往app查看评论内容

#PARP#

恒瑞医药PARP抑制剂获批上市

2020-12-16

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Eur Urol：ATM缺失的晚期前列腺癌：PARP和ATR抑制剂

2020-12-15

lishiwen (审核中...)

前往app查看评论内容

#PARP#

PARP抑制剂Lynparza在欧洲获得重大成功！同时获批治疗卵巢癌和前列腺癌

2020-11-11

lishiwen (审核中...)

前往app查看评论内容

#PARP#

J Clin Oncol：携带PALB2胚系突变的乳腺癌患者也可从PARPi治疗中获益

2020-11-04

lishiwen (审核中...)

前往app查看评论内容

#PARP#

中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO

2020-09-21

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Neoplasia ：公布PARP抑制剂晚期卵巢2期临床数据，有望为患者开启“去化疗”治疗新时代

2020-09-21

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效

2020-08-30

lishiwen (审核中...)

前往app查看评论内容

#PARP#

新型PARP抑制剂Stenoparib：在临床前研究中显示出抗新冠病毒活性！

2020-08-28

lishiwen (审核中...)

前往app查看评论内容

#PARP#

姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查

2020-06-21

lishiwen (审核中...)

前往app查看评论内容

#PARP#

欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗

2020-06-06

lishiwen (审核中...)

前往app查看评论内容

#PARP#

FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌

2020-05-24

lishiwen (审核中...)

前往app查看评论内容

#PARP#

尹如铁教授：HRD检测扩大复发性卵巢癌后线治疗获益人群，国内产品首次用于PARPi临床试验入组HRD检测

2020-05-21

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Rubraca在美国获批，成为获批治疗前列腺癌的PARP抑制剂

2020-05-18

lishiwen (审核中...)

前往app查看评论内容

#PARP#

FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗

2020-05-03

lishiwen (审核中...)

前往app查看评论内容

#PARP#

阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期

2020-04-27

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果

2020-04-21

lishiwen (审核中...)

前往app查看评论内容

#PARP#

再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查

2020-04-20

lishiwen (审核中...)

前往app查看评论内容

#PARP#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-03-16

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

Nat Commun：PARP1通过上调Runx2促进血管钙化

2020-02-29

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗

2020-02-27

科室
- - 订阅+
  - 更多科室
工具
服务